2. Academic Validation
  3. Gut-derived hyodeoxycholate reprograms the spleen-eye immunometabolic axis to suppress autoimmune uveitis

Gut-derived hyodeoxycholate reprograms the spleen-eye immunometabolic axis to suppress autoimmune uveitis

  • Cell Death Differ. 2026 Mar 11. doi: 10.1038/s41418-026-01696-8.
Yitao Li # 1,  Weijia Zheng # 2,  Jiao Ma 1,  Lu Liu 2,  Xintong Yang 1,  Junliang Kuang 3,  Nickie Chan 1,  Chengqiang Wang 1,  Yang Li 3,  Aihua Zhao 3,  Ruonan Wang 4 5,  Xiaojiao Zheng 3,  Gerry Melino 6,  Aiping Lu 7,  Xiaolu Yang 8 9,  Wei Jia 10 11 12
Affiliations

Affiliations

  • 1 School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China.
  • 2 Department of Pharmacology and Pharmacy, The University of Hong Kong, Hong Kong, China.
  • 3 Center for Translational Medicine and Shanghai Key Laboratory of Diabetes Mellitus, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • 4 Department of Ophthalmology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • 5 National Clinical Research Center for Eye Diseases, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • 6 Department of Experimental Medicine, University of Rome "Tor Vergata", Rome, Italy. [email protected].
  • 7 School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China. [email protected].
  • 8 Department of Ophthalmology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. [email protected].
  • 9 National Clinical Research Center for Eye Diseases, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. [email protected].
  • 10 School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China. [email protected].
  • 11 Department of Pharmacology and Pharmacy, The University of Hong Kong, Hong Kong, China. [email protected].
  • 12 Center for Translational Medicine and Shanghai Key Laboratory of Diabetes Mellitus, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China. [email protected].
  • # Contributed equally.
PMID: 41813862 DOI: 10.1038/s41418-026-01696-8
Abstract

Autoimmune uveitis (AU) lacks targeted therapies beyond immunosuppression. We identified hyodeoxycholate (HDCA), a gut-derived secondary bile acid, as a key immunometabolic regulator in AU. Metabolomics revealed systemic depletion of HDCA and oleic acid (C18:1n9) in AU patients and experimental AU (EAU) mice, correlating with disease severity. HDCA administration effectively attenuated EAU by reducing pro-inflammatory cytokines (IL-1β, IL-6, and TNF-α) and elevating IL-10. Mechanistically, HDCA inhibits Farnesoid X Receptor in splenic red pulp macrophages, activating SREBP1c-dependent fatty acid synthase, which enhances oleic acid production. Systemic oleic acid suppresses ocular Th17 responses and promotes M2 macrophage polarization, enhancing anti-inflammatory immunity. These findings define a spleen-to-eye immunometabolic axis driven by HDCA-mediated macrophage reprogramming, positioning HDCA as a promising therapeutic for AU.

Figures
Products